Lassa Fever Treatment Market Players:
- Pfizer, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Novartis International AG
- Sanofi S.A.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Abbott Laboratories
- Inovio Pharmaceuticals Inc
- Cipla Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of lassa fever treatment is evaluated at USD 709.05 million.
The global lassa fever treatment market size was worth over USD 657.01 million in 2025 and is poised to grow at a CAGR of around 8.8%, reaching USD 1.53 billion revenue by 2035.
The Middle East & Africa lassa fever treatment market will hold around 33% share, expected to grow by 2035, fueled by lack of sanitation services and rising healthcare investment.
Key players in the market include Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited.
